3:15 pm-3:25 pm

Welcome and Framing of Discussion

Indu Kohaar, PhD, National Cancer Institute;

Jeffrey Tosoian, MD, Vanderbilt University Medical Center

N/A

4:05 pm

Industry Talks on Potential Collaborations (40 min – 10 min each)

N/A

N/A

3:25 pm-3:35 pm

Creatv MicroTech, Inc.

Expanding the Clinical Utility of Blood Based Biopsies in Cancer Screening, Diagnostics and Drug Prediction Using Circulating Stromal Cells

Daniel L. Adams, Chief Scientific Officer, Creatv Bio, Division of Creatv MicroTech

01

3:35 pm-3:45 pm

Meso Scale Diagnostics, LLC

Bridging Discovery and Validation in Prostate Cancer Biomarkers

Hans Layman, PhD, Executive Director Oncology & Scientific Affairs, Meso Scale Diagnostics, LLC

02

3:45 pm-3:55 pm

Beckman Coulter

Advancing Prostate Care: phi at Beckman Coulter

Lindsay Sun, MD, Senior Medical Director, Beckman Coulter

03

3:55 pm-4:05 pm

Alluz Diagnostics

Clinical Translation for Prostate Cancer Tests to Address High Unmet Clinical Needs

Gerard Davis, PhD, Alluz Diagnostics

04

4:05 pm-4:45 pm

Cross-Center and Industry Collaborations

Martin Sanda, MD, Emory University

John Semmes, PhD, Eastern Virginia Medical School

05

4:45 pm-4:55 pm

Break

N/A

N/A

4:55 pm-5:25 pm

Promising Approaches and PCa Biomarkers

Dan Chan, PhD, Hui Zhang, PhD

Johns Hopkins University

06

5:25 pm-5:45 pm

NCI EDRN MRI Biomarker Study and Reference Set (PMRI)- Status and Potential Outcome

John Wei, MD; Simpa Salami, MD

University of Michigan

07

5:45 pm-6:15 pm

Vision for Next Cycle of EDRN

Indu Kohaar, PhD, National Cancer Institute;

Jeffrey Tosoian, MD, Vanderbilt University Medical Center

08